Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- Ask the CIO
- Connected Government
- Consolidating Mission-critical Systems
- Constituent Servicing
- The Data Privacy Imperative: Safeguarding Sensitive Data
- Eliminating the Pitfalls: Steps to Virtualization in Government
- Federal Executive Forum
- Federal Tech Talk
- Government Cloud Brokerage: Who, What, When, Where, Why?
- Government Mobility
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Mobile Device Management
- The Modern Federal Threat Landscape
- Moving to the Cloud. What's the best approach for me
- Navigating Tough Choices in Government Cloud Computing
- Satellite Communications: Acquiring SATCOM in Tight Times
- Transformative Technology: Desktop Virtualization in Government
- Understanding the Intersection of Customer Service and Security in the Cloud
Shows & Panels
EU regulator: No more problems with Roche drugs
Friday - 11/22/2013, 2:18pm EST
LONDON (AP) -- The European Medicines Agency says it has finished an investigation of the way pharmaceutical giant Roche reported side effects for 19 drugs in the U.S. and has found no new safety concerns.
Last year, the agency took action against Roche after alleging the Swiss drug maker failed to properly report side effects for the medicines, including the cancer drugs Avastin, Herceptin and Xeloda. British authorities said there were "serious shortcomings" in how Roche AG reported potential problems.
In a statement Tuesday, the European regulator said further safety data on the medicines showed "the balance of benefits and risks of these medicines has not been affected and there is no new advice regarding their use." It said Roche continued to provide additional information as part of their obligatory follow-up.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.